Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) EBITDA Margin (2020 - 2025)

Biofrontera has reported EBITDA Margin over the past 6 years, most recently at 26.66% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4029.0% year-over-year to 26.66%; the TTM value through Dec 2025 reached 27.2%, up 1891.0%, while the annual FY2025 figure was 27.21%, 1890.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 26.66% at Biofrontera, up from 89.84% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 26.66% in Q4 2025 and troughed at 371.6% in Q3 2021.
  • A 5-year average of 75.72% and a median of 59.57% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -29952bps in 2021 and later soared 28740bps in 2022.
  • Year by year, EBITDA Margin stood at 20.74% in 2021, then crashed by -165bps to 55.02% in 2022, then surged by 34bps to 36.48% in 2023, then skyrocketed by 63bps to 13.63% in 2024, then skyrocketed by 296bps to 26.66% in 2025.
  • Business Quant data shows EBITDA Margin for BFRI at 26.66% in Q4 2025, 89.84% in Q3 2025, and 56.25% in Q2 2025.